TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3085136

Group type: EXPERIMENTAL
Intervention: 5 mg fluphenazine decanoate
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 25 mg fluphenazine decanoate
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined dosage groups (5 mg and 25 mg)
Number of subjects: 45
Study: 31741360

Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% lotion
Number of subjects: 606

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 606
Study: 29056392

Group type: EXPERIMENTAL
Intervention: 1-minute continuous chest compressions
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2-minute continuous chest compressions
Number of subjects: 36

Group type: COMPARATOR
Intervention: 1-minute vs 2-minute groups
Number of subjects: 36
Study: 26862696

Group type: EXPERIMENTAL
Intervention: Palifermin, 60 mg/kg, intravenously as a single dose 3 days before and after transplant conditioning regimen cycle
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (placebo treatment)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 46
Study: 25229957

Group type: EXPERIMENTAL
Intervention: Structural Family Therapy (SFT)
Number of subjects: 40
Study: 22476908

Group type: EXPERIMENTAL
Intervention: 1.5 T CMR
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 3 T CMR
Number of subjects: 34

Group type: COMPARATOR
Intervention: FFR
Number of subjects: 34
Study: 21417122

Group type: EXPERIMENTAL
Intervention: Ozone pretreatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Conventional fissure sealant (Fissurit F) with ozone pretreatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Self-etch adhesive (Clearfil Protect Bond) with ozone pretreatment
Number of subjects: 48
Study: 17592913

Group type: EXPERIMENTAL
Intervention: Panic-Focused Psychodynamic Psychotherapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Applied Relaxation Training
Number of subjects: 49
Study: 16518702

Group type: EXPERIMENTAL
Intervention: AA genotype carrying patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: AG genotype carrying patients
Number of subjects: 0
Study: 11954869

Group type: EXPERIMENTAL
Intervention: BTX‐A from original bulk toxin source
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: BTX‐A from current bulk toxin source
Number of subjects: 133
Study: 10413279

Group type: EXPERIMENTAL
Intervention: Allogeneic RBCs (n = 17)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: WBC-reduced RBCs (n = 14)
Number of subjects: 47
Study: 8689462

Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronic acid (HA) - 5 injections at weekly intervals
Number of subjects: 63

Group type: COMPARATOR
Intervention: Intra-articular triamcinolone hexacetonide (TH) - 20 mg followed by 4 placebo (saline) injections
Number of subjects: 63
Study: 2088110

Group type: EXPERIMENTAL
Intervention: CDP-choline
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control
Number of subjects: 210
Study: 698165

Group type: EXPERIMENTAL
Intervention: 1 mg cyanocobalamin injection, three times weekly for 6 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo injection, three times weekly for 6 weeks
Number of subjects: 31
Study: 30664093

Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise Program (CSEP), 16 sessions, 3 days per week for 6 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise Program (CSEP)
Number of subjects: 30
Study: 29282009

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg orally three times daily from recruitment to 32 weeks gestation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo tablets orally three times daily from recruitment to 32 weeks gestation
Number of subjects: 0
Study: 25476463

Group type: EXPERIMENTAL
Intervention: Pre-operative prism adaptation test (PAT) performed in 18 patients (Group 1)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No pre-operative prism adaptation test (Group 2)
Number of subjects: 38
Study: 23278907

Group type: EXPERIMENTAL
Intervention: No-touch method
Number of subjects: 171

Group type: COMPARATOR
Intervention: Classical sterile method
Number of subjects: 171
Study: 21191143

Group type: EXPERIMENTAL
Intervention: 10 g essential amino acids with 10 g l-arginine (ARG)
Number of subjects: 8

Group type: COMPARATOR
Intervention: isonitrogenous control (CON)
Number of subjects: 8
Study: 20053252

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 2397

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 2397
Study: 17876177

Group type: EXPERIMENTAL
Intervention: Individualized information intervention
Number of subjects: 324

Group type: COMPARATOR
Intervention: Generic information intervention
Number of subjects: 324
Study: 15235055

Group type: EXPERIMENTAL
Intervention: Intravenous Atrial Natriuretic Peptide (ANP)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard conventional therapy (Control)
Number of subjects: 58
Study: 14564675

Group type: EXPERIMENTAL
Intervention: Leucoselect‐Phytosome (LP)
Number of subjects: 24
Study: 10670160

Group type: COMPARATOR
Intervention: SF6‐gas tamponade
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Silicone‐oil tamponade
Number of subjects: 54
Study: 7474675

Group type: EXPERIMENTAL
Intervention: Strict blood pressure control (DBP 65 to 80 mm Hg)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conventional blood pressure control (DBP 85 to 95 mm Hg)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Secondary analysis of combined outcomes
Number of subjects: 87
Study: 1964599

Group type: EXPERIMENTAL
Intervention: Continuous oral acyclovir therapy for the suppression of recurrent genital herpes simplex virus infection
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Continuous oral acyclovir therapy
Number of subjects: 48
Study: 377878

Group type: EXPERIMENTAL
Intervention: NPH insulin with regular insulin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PZI insulin with regular insulin
Number of subjects: 10
Study: 31860606

Group type: EXPERIMENTAL
Intervention: Single-dose stellate ganglion block (SGB) with 5 ml of 0.5% ropivacaine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Single-dose stellate ganglion block (SGB)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 29670279

Group type: COMPARATOR
Intervention: F-652 (2.0 µg/kg, SC)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: F-652 (IV infusion at 2.0, 10, 30, and 45 µg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: F-652 (IV infusion)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: F-652 (45 µg/kg, IV)
Number of subjects: 6
Study: 28936675

Group type: EXPERIMENTAL
Intervention: Reconnection to mechanical ventilation for 1 hour after successful spontaneous breathing trial (rest group)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Direct extubation (control group)
Number of subjects: 470
Study: 25440265

Group type: EXPERIMENTAL
Intervention: CS+filter
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: CS
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: filter
Number of subjects: 716

Group type: COMPARATOR
Intervention: neither CS nor filter
Number of subjects: 716
Study: 23684013

Group type: EXPERIMENTAL
Intervention: Injection of autologous blood (ABI) alone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intramaxillary fixation (IMF) alone for 4 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Injection of autologous blood (ABI) and intramaxillary fixation (IMF) for 4 weeks
Number of subjects: 48
Study: 21063429

Group type: COMPARATOR
Intervention: Standard formula (SF: 14.1 g/l protein, 662 kcal/l)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Experimental formula (EF: 12.8 g/l protein, 662 kcal/l)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 336
Study: 19302900

Group type: EXPERIMENTAL
Intervention: Risedronate 100 mg/mo
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Risedronate 150 mg/mo
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Risedronate 200 mg/mo
Number of subjects: 370

Group type: COMPARATOR
Intervention: Risedronate 5 mg/d (active control)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Risedronate 150 mg/mo and 200 mg/mo
Number of subjects: 370

Group type: COMPARATOR
Intervention: Risedronate 5 mg/d
Number of subjects: 370
Study: 17316103

Group type: EXPERIMENTAL
Intervention: Self-directed training (written text-graphic directions for use with patient-assistance phone number)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Intensive training (same DFU, personal training by study personnel, inspiratory flow rate coaching)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both training methods (self-directed and intensive)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intensive training
Number of subjects: 102
Study: 15355142

Group type: EXPERIMENTAL
Intervention: Emotional words in reading, lexical decision, and color naming tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral words in a single block
Number of subjects: 0
Study: 11150007

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (TSD)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Partial sleep deprivation (PSD)
Number of subjects: 42
Study: 10049522

Group type: EXPERIMENTAL
Intervention: Interferons (IFN) beta and gamma in combination with hormonotherapy (Megace or Tamoxifen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline levels of sIL‐2R and of IFN‐gamma
Number of subjects: 0
Study: 8281698

Group type: EXPERIMENTAL
Intervention: Aspirin plus anticoagulation (aspirin 162.5 mg daily plus heparin followed by aspirin 162.5 mg daily plus warfarin)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Aspirin alone (162.5 mg daily)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Combination therapy (aspirin plus anticoagulation)
Number of subjects: 214
Study: 30502489

Group type: EXPERIMENTAL
Intervention: Vaccine strain (mumps vaccine)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Wild-type virus
Number of subjects: 570

Group type: COMPARATOR
Intervention: Vaccine strain vs Wild-type virus
Number of subjects: 570
Study: 27402475

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (250,000 IU, one-time oral dose)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 25967093

Group type: EXPERIMENTAL
Intervention: Intensified work-related rehabilitation aftercare program (including functional capacity training, psychosocial groups, social counseling, relaxation training, and exercise therapy)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Standard intensified rehabilitation aftercare (consisting of only exercise therapy)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Intensified work-related rehabilitation aftercare program
Number of subjects: 307

Group type: COMPARATOR
Intervention: Standard intensified rehabilitation aftercare
Number of subjects: 307
Study: 25549015

Group type: EXPERIMENTAL
Intervention: Ginger (as a drug)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22910440

Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel (C/P) plus motesanib
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel (C/P) plus bevacizumab
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel (C/P)
Number of subjects: 1400
Study: 19184059

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab
Number of subjects: 3103

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 3103
Study: 16950885

Group type: EXPERIMENTAL
Intervention: Élite racing drivers
Number of subjects: 18

Group type: COMPARATOR
Intervention: Physically active controls
Number of subjects: 18
Study: 15202299

Group type: EXPERIMENTAL
Intervention: Cytotoxic and glucocorticoid therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Before therapy
Number of subjects: 43
Study: 11330583

Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel hemorrhoidectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Electrocautery hemorrhoidectomy
Number of subjects: 50
Study: 9264147

Group type: EXPERIMENTAL
Intervention: RU 486 (200 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8302150

Group type: EXPERIMENTAL
Intervention: 2 mg epidural morphine in 10 mL normal saline with epinephrine 0.1 mg (1:100,000, 10 micrograms/mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2 mg epidural morphine in 10 mL normal saline without epinephrine
Number of subjects: 60
Study: 3731824

Group type: EXPERIMENTAL
Intervention: 160 mg sustained-release oxprenolol once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 25 mg hydrochlorothiazide/50 mg triamterene once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of 160 mg sustained-release oxprenolol and 25 mg hydrochlorothiazide/50 mg triamterene once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: 160 mg sustained-release oxprenolol alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: 25 mg hydrochlorothiazide/50 mg triamterene alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide treatment
Number of subjects: 30
Study: 31504090

Group type: EXPERIMENTAL
Intervention: Eating sweets (n = 60)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Calorie-equivalent bland food (n = 60)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Watching a video (n = 30)
Number of subjects: 150
Study: 28815997

Group type: EXPERIMENTAL
Intervention: Twice-daily sustained-release (SR) paracetamol (2 × 1000 mg twice daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: All formulations
Number of subjects: 28
Study: 27514255

Group type: EXPERIMENTAL
Intervention: Exposure to abnormal acceleration of sea state
Number of subjects: 60
Study: 25008861

Group type: EXPERIMENTAL
Intervention: B haplotypes (activating KIR genes)
Number of subjects: 517
Study: 22811926

Group type: EXPERIMENTAL
Intervention: Cranberry capsules (1 capsule/day) for 6 months after a wash-out period
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cranberry capsules (1 capsule/day)
Number of subjects: 20
Study: 20173092

Group type: EXPERIMENTAL
Intervention: SE-1 (50 microM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SE-2 (50 microM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SE-3 (200 microM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SE-1 (100 microM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SE-2 (100 microM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SE-3 (100 microM)
Number of subjects: 0
Study: 18489612

Group type: EXPERIMENTAL
Intervention: Darifenacin 15 mg for 1 week
Number of subjects: 15

Group type: COMPARATOR
Intervention: Atropine (nonselective muscarinic antagonist)
Number of subjects: 15
Study: 16003020

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 2064

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2064
Study: 11849656

Group type: EXPERIMENTAL
Intervention: Quinapril (ACE inhibitor)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control group (ACE D homozygotes)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 253
Study: 10528882

Group type: EXPERIMENTAL
Intervention: Plasma nitrate levels during acute gastroenteritis
Number of subjects: 43

Group type: COMPARATOR
Intervention: Plasma nitrate levels during acute pneumonia
Number of subjects: 43

Group type: COMPARATOR
Intervention: Plasma nitrate levels during febrile urinary tract infection
Number of subjects: 43

Group type: COMPARATOR
Intervention: Plasma nitrate levels in 20 patients with severe pneumonia or UTI
Number of subjects: 43
Study: 7746935

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation with an inspiratory mask
Number of subjects: 85
Study: 2386447

Group type: EXPERIMENTAL
Intervention: d-amphetamine (10 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: scopolamine (1.0 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 7389389

Group type: EXPERIMENTAL
Intervention: Cefaclor 250 mg 3-times daily
Number of subjects: 101

Group type: COMPARATOR
Intervention: Amoxycillin 250 mg 3-times daily
Number of subjects: 101
Study: 31775843

Group type: EXPERIMENTAL
Intervention: SHGBZK treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 100
Study: 30249190

Group type: EXPERIMENTAL
Intervention: Noncontrast MRI
Number of subjects: 416

Group type: COMPARATOR
Intervention: Noncontrast US
Number of subjects: 416
Study: 27835963

Group type: EXPERIMENTAL
Intervention: Moulded flip-flop footwear (Foot Bio-Tec©) with a moulded foot-bed
Number of subjects: 108

Group type: COMPARATOR
Intervention: Footwear education and instructions to wear their normal footwear
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Moulded flip-flop footwear (Foot Bio-Tec©)
Number of subjects: 108
Study: 24599676

Group type: EXPERIMENTAL
Intervention: Balneotherapy plus physical therapy (n=37)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Physical therapy alone (n=44)
Number of subjects: 81
Study: 22383668

Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19128455

Group type: EXPERIMENTAL
Intervention: AS+AQ
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: AS+SP
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: AQ+SP
Number of subjects: 397
Study: 17559990

Group type: EXPERIMENTAL
Intervention: Intranasal (IN) administration of 15, 30, or 60mcg of trivalent inactivated influenza vaccine
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) administration of 15, 30, or 60mcg of trivalent inactivated influenza vaccine
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Combined IM and IN administration of trivalent inactivated influenza vaccine
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo (IN and IM)
Number of subjects: 243
Study: 15607399

Group type: EXPERIMENTAL
Intervention: Single-chamber detection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dual-chamber detection
Number of subjects: 60
Study: 11792089

Group type: EXPERIMENTAL
Intervention: Meta-analysis of controlled clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meta-analysis
Number of subjects: 0
Study: 9236649

Group type: EXPERIMENTAL
Intervention: Vacuum aspiration
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Medical abortion using mifepristone and gemeprost
Number of subjects: 140

Group type: COMPARATOR
Intervention: Both methods
Number of subjects: 140
Study: 7969677

Group type: EXPERIMENTAL
Intervention: Pure oxygen breathing
Number of subjects: 32

Group type: COMPARATOR
Intervention: Air breathing
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Post-oxygen breathing
Number of subjects: 32
Study: 3655856

Group type: COMPARATOR
Intervention: CAF chemotherapy (cyclophosphamide + doxorubicin + 5‐fluorouracil [5‐FU])
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAF plus tamoxifen (TCAF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CAF chemotherapy (for ER+ patients)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CAF chemotherapy (for ER- patients)
Number of subjects: 0
Study: 29023249

Group type: EXPERIMENTAL
Intervention: 1-Hz repetitive transcranial magnetic stimulation (rTMS) over contralesional leg motor cortex for 15 minutes followed by 45 minutes of physical therapy for 15 sessions over 3 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham 1-Hz repetitive transcranial magnetic stimulation (rTMS) over contralesional leg motor cortex for 15 minutes followed by 45 minutes of physical therapy for 15 sessions over 3 weeks
Number of subjects: 38
Study: 25956688

Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sham kinesiotaping (sham KT)
Number of subjects: 73
Study: 24172209

Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER (40 to 120 mg/d)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study: 22709688

Group type: EXPERIMENTAL
Intervention: Platelet count outside of the normal range during follow-up
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Elevated WBC count during follow-up
Number of subjects: 776
Study: 20155988

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg/day (monotherapy)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg/day with pravastatin 10 mg/day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg/day with rosuvastatin 2.5 mg/day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ezetimibe (both monotherapy and combination therapy)
Number of subjects: 46
Study: 18084989

Group type: EXPERIMENTAL
Intervention: Group(VC)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Group(21cm)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Group(Cuff)
Number of subjects: 88
Study: 16360048

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 79
Study: 11919665

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg on days 1-8, 100 mg on days 9-15)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg on days 1-8, 40 mg on days 9-15)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 10344359

Group type: EXPERIMENTAL
Intervention: Hb concentration of 14 g/dl ([Hb]14)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Hb concentration of 10 g/dl ([Hb]10)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Comparison of resting plasma [K+] at [Hb]10 and [Hb]14
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Delta[K+] per unit work performed at different Hb levels
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lactate concentration during exercise at both target [Hb] levels
Number of subjects: 14
Study: 7628179

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water
Number of subjects: 8
Study: 2035006

Group type: EXPERIMENTAL
Intervention: Salt loading (+6.1 +/- 2.8 g NaCl/d = 105 +/- 48 mmol Na)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Salt restriction
Number of subjects: 14

Group type: COMPARATOR
Intervention: Loading with sodium citrate in equimolar concentrations (+140 +/- 40 ml Shohl's solution = 120 +/- 34 mmol Na)
Number of subjects: 14